Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Sees Significant Increase in Short Interest

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totaling 33,356 shares, a growth of 593.2% from the August 15th total of 4,812 shares. Currently, 3.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,671,352 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, June 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Price Performance

Biodexa Pharmaceuticals stock opened at $1.30 on Friday. Biodexa Pharmaceuticals has a 52 week low of $0.61 and a 52 week high of $59.40. The stock has a fifty day moving average of $1.52 and a 200-day moving average of $2.90.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC bought a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals comprises 0.6% of Sabby Management LLC’s portfolio, making the stock its 10th biggest holding. Sabby Management LLC owned approximately 28.04% of Biodexa Pharmaceuticals as of its most recent SEC filing. Institutional investors own 17.51% of the company’s stock.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.